Comparison · NCT02047344-87537fdf
Progression-free Survival Rate/KRAS Negative Group vs Progression-free Survival Rate/KRAS Mutant Group: Progression Free Survival Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Progression-free Survival Rate/KRAS Negative Group vs Progression-free Survival Rate/KRAS Mutant Group: Progression Free Survival Rate. Trial comparisons, record NCT02047344-87537fdf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02047344-87537fdf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.267 | 0.109 | 0.52 | wilson | |
| Risk in group 2 | 0 | 0 | 0.204 | wilson | |
| Risk difference, group 1 minus group 2 | 0.267 | 0.00892 | 0.52 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Progression-free Survival Rate/KRAS Negative Group than on Progression-free Survival Rate/KRAS Mutant Group | 3.75 | 1.92 | 112 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Progression-free Survival Rate/KRAS Negative Group | 200mg TID for treating KRAS negative patients 12 weeks | 4 | 15 | OG000 |
| Group 2 | Progression-free Survival Rate/KRAS Mutant Group | 200mg TID for treating KRAS negative patients 12 weeks | 0 | 15 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Progression Free Survival Rate
- Description
Tumor response will be assessed at 6 week intervals during the first treatment cycle using the RECIST criteria, version 1.1. Each patient will be assigned one of the following categories: 1) complete response (CR), 2) partial response (PR), 3) stable disease (SD), or 4) progressive disease (PD). Patients who died from any cause or discontinued the study for any reason without a post screening or Week 12 tumor assessment will be considered as failing to respond to treatment.
- Time frame
- 12 weeks
- Population
- Defined as the proportion of patients alive and progression free at Week 12.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
- NCT number
- NCT02047344
- Phases
- PHASE2
- Conditions
- Non-small Cell Lung Cancer Stage IV
- Interventions
- Antroquinonol
- Lead sponsor
- Golden Biotechnology Corporation
- Results first posted
- 2019-12-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02047344?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02047344-87537fdf